Skip to content

Mazdutide: Side Effects & Safety

Part of the Mazdutide Complete Guide

Partner

Research Peptides

BioLongevity Labs15% Off
Shop Peptides at BioLongevity Labs

We may earn a commission if you purchase through this link, at no extra cost to you.

Overall Safety Profile

Mazdutide's side effect profile is consistent with GLP-1 agonist-class medications, with GI effects predominating. The glucagon component adds theoretical considerations for glucose control and cardiovascular effects that require ongoing monitoring in Phase 3 trials.

Reported Side Effects

  • Nausea and vomiting: Most common, consistent with GLP-1 class
  • Diarrhea
  • Decreased appetite
  • Heart rate increase: Mild, consistent with glucagon effects
  • Injection site reactions: Mild

Important Limitations

Long-term safety data beyond Phase 3 trial durations is not available. The effects of chronic glucagon receptor activation on hepatic function, cardiac health, and amino acid metabolism require further characterization. Mazdutide is not approved for use in any market.

Potential Contraindications

  • Personal/family history of MTC or MEN2 (GLP-1 class warning)
  • Severe hepatic or renal impairment
  • Pregnancy and breastfeeding

Researching peptides? We did the hard part.

Get our free Peptide Starter Kit — the 5 most researched compounds, simplified into one actionable guide.

Related Guides

PI

Peptides Insider Editorial Team

Our content is reviewed for accuracy and grounded in peer-reviewed research where available. We do not provide medical advice. Always consult a qualified healthcare professional.